Regional Differences in Serotonin Transporter Occupancy by Escitalopram: An [11C]DASB PK-PD Study

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Clinical Pharmacokinetics

• Publication date

  2017-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s40262-016-0444-xPMID 27557550
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• X-ray structures and mechanism of the human serotonin transporter

  2016cited by this paper
• Altered serotonin transporter binding potential in patients with obsessive-compulsive disorder under escitalopram treatment: [11C]DASB PET study

  2015cited by this paper
• Regional differences in SERT occupancy after acute and prolonged SSRI intake investigated by brain PET

  2014cited by this paper
• Extrastriatal binding of [123I]FP-CIT in the thalamus and pons: gender and age dependencies assessed in a European multicentre database of healthy controls

  2014cited by this paper
• Serotonin 5-HT1A Receptors as Targets for Agents to Treat Psychiatric Disorders: Rationale and Current Status of Research

  2013cited by this paper
• Effect of a single dose of escitalopram on serotonin concentration in the non-human and human primate brain.

  2013cited by this paper
• Escitalopram tolerability as mono- versus augmentative therapy in patients with affective disorders: a naturalistic study

  2013cited by this paper
• Predicting Brain Occupancy from Plasma Levels using PET: Superiority of Combining Pharmacokinetics with Pharmacodynamics while Modeling the Relationship

  2012cited by this paper
• Measuring endogenous changes in serotonergic neurotransmission in humans: a [11C]CUMI-101 PET challenge study

  2012cited by this paper
• Normative database of the serotonergic system in healthy subjects using multi-tracer PET

  2012cited by this paper
• Serotonin transporter occupancy with TCAs and SSRIs: a PET study in patients with major depressive disorder

  2012cited by this paper
• Quantification of Ligand PET Studies using a Reference Region with a Displaceable Fraction: Application to Occupancy Studies with [11C]-DASB as an Example

  2012cited by this paper
• What is the optimal dose of escitalopram for the treatment of obsessive–compulsive disorder? A naturalistic open-label study

  2011cited by this paper
• Efficacy, safety and tolerability of escitalopram in doses up to 50 mg in Major Depressive Disorder (MDD): an open-label, pilot study

  2011cited by this paper
• Reward and the serotonergic system.

  2010cited by this paper
• Long‐lasting target binding and rebinding as mechanisms to prolong in vivo drug action

  2010cited by this paper
• Open-label study of high (30 mg) and moderate (20 mg) dose escitalopram for the treatment of obsessive–compulsive disorder

  2009cited by this paper
• Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis.

  2009cited by this paper
• High‐dose escitalopram in the treatment of binge‐eating disorder with obesity: a placebo‐controlled monotherapy trial

  2008cited by this paper
• High-dose escitalopram for the treatment of obsessive–compulsive disorder

  2008cited by this paper
• Effects of Citalopram Infusion on the Serotonin Transporter Binding of [11C]DASB in Healthy Controls

  2008cited by this paper
• Estimates of Serotonin and Norepinephrine Transporter Inhibition in Depressed Patients Treated with Paroxetine or Venlafaxine

  2008cited by this paper
• Escitalopram Therapy for Major Depression and Anxiety Disorders

  2007cited by this paper
• PET measurement of serotonin transporter occupancy: a comparison of escitalopram and citalopram.

  2007cited by this paper
• The serotonin transporter in rhesus monkey brain: comparison of DASB and citalopram binding sites.

  2006cited by this paper
• Acute occupancy of brain serotonin transporter by sertraline as measured by [11C]DASB and positron emission tomography.

  2006cited by this paper
• Analysis of Functional Brain Images Using Population-Based Probabilistic Atlas

  2005cited by this paper
• The Pharmacokinetics of Escitalopram After Oral and Intravenous Administration of Single and Multiple Doses to Healthy Subjects

  2005cited by this paper
• Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [11C]DASB positron emission tomography study.

  2004cited by this paper
• Linearized Reference Tissue Parametric Imaging Methods: Application to [11C]DASB Positron Emission Tomography Studies of the Serotonin Transporter in Human Brain

  2003cited by this paper
• Escitalopram

  2002cited by this paper
• Significant dissociation of brain and plasma kinetics with antipsychotics

  2002cited by this paper
• Occupancy of serotonin transporters by paroxetine and citalopram during treatment of depression: a [(11)C]DASB PET imaging study.

  2001cited by this paper
• Quantification of F-18 FDG PET Images in Temporal Lobe Epilepsy Patients Using Probabilistic Brain Atlas

  2000cited by this paper
• Imaging the serotonin transporter with positron emission tomography: initial human studies with [11C]DAPP and [11C]DASB

  2000cited by this paper
• Validation and Reproducibility of Measurement of 5-HT1A Receptor Parameters with [carbonyl-11C]WAY-100635 in Humans: Comparison of Arterial and Reference Tissue Input Functions

  2000cited by this paper
• A review of central 5-HT receptors and their function.

  1999cited by this paper
• The Efficiency Concept in Pharmacodynamics

  1999cited by this paper
• Effects of Chronic Antidepressant Treatments on Serotonin Transporter Function, Density, and mRNA Level

  1999cited by this paper
• Estimating Potency for the Emax-Model Without Attaining Maximal Effects

  1998cited by this paper
• Evaluation of the importance of rebinding to receptors in slowing the approach to equilibrium of high‐affinity PET and SPECT radiotracers

  1998cited by this paper
• Structured clinical interview for DSM-IV axis I disorders : SCID-I : clinical version : scoresheet

  1997cited by this paper
• Effects of acute fluoxetine on extracellular serotonin levels in the raphe: an in vivo microdialysis study.

  1995cited by this paper
• Interaction between a selective 5‐HT1A receptor antagonist and an SSRI in vivo: effects on 5‐HT cell firing and extracellular 5‐HT

  1995cited by this paper
• Fluvoxamine preferentially increases extracellular 5-hydroxytryptamine in the raphe nuclei: an in vivo microdialysis study.

  1992cited by this paper
• Effects of a selective 5-HT reuptake blocker, citalopram, on the sensitivity of 5-HT autoreceptors: Electrophysiological studies in the rat brain

  1986cited by this paper
• Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to d-tubocurarine.

  1980cited by this paper
• Simultaneous modeling of pharmacokinetics and pharmacodynamics: Application to d‐tubocurarine

  1979cited by this paper

• Enhanced CYP2C19-mediated drug-drug interaction risk with escitalopram in geriatric populations

  2026cites this paper
• Escitalopram Dose Optimization During Pregnancy: A PBPK Modeling Approach

  2025cites this paper
• How to Determine a Therapeutic Reference Range for a Psychotropic Drug Systematically? Recommendations of the TDM Task Force of the AGNP

  2025cites this paper
• Role of Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors and Psychedelics in the Treatment of Major Depressive Disorder: A Perspective on Mechanistic Insight and Current Status.

  2025cites this paper
• Modulation of autism-associated serotonin transporters by palmitoylation: Insights into the molecular pathogenesis and targeted therapies for autism spectrum disorder

  2025cites this paper
• Modulation of Autism-Associated Serotonin Transporters by Palmitoylation: Insights into the Molecular Pathogenesis and Targeted Therapies for Autism Spectrum Disorder.

  2025cites this paper
• Update Lessons from PET Imaging Part II: A Systematic Critical Review on Therapeutic Plasma Concentrations of Antidepressants

  2024cites this paper
• Systematic review and meta-analysis on the therapeutic reference range for escitalopram: Blood concentrations, clinical effects and serotonin transporter occupancy

  2022cites this paper
• Beyond monoamines: I. Novel targets and radiotracers for Positron emission tomography imaging in psychiatric disorders

  2022cites this paper
• The relationship between dose and serotonin transporter occupancy of antidepressants—a systematic review

  2021cites this paper
• Direct visualization of an antidepressant analog using surface-enhanced Raman scattering in the brain.

  2020cites this paper
• Serotonin Transporter Binding Potentials in Brain of Juvenile Monkeys 1 Year After Discontinuation of a 2-Year Treatment With Fluoxetine.

  2019cites this paper
• PET Occupancy and Competition in Translational Medicine and CNS Drug Development

  2019cites this paper
• Tracer Kinetics in Radionanomedicine

  2018cites this paper
• Small Molecule PET Tracers in Drug Discovery.

  2017cites this paper